2023 Agenda

Download 2023 Brochure
Flip through our 2023 conference brochure and discover what’s new this year.
- Jump to:
- At a Glance
- Day 1
- Day 2
- Print-friendly Format
Day 1 - Thursday, January 19, 2023
Day 2 - Friday, January 20, 2023
Day 1 - Thursday, January 19, 2023
7:45 |
Coffee and ConnectionsWomen of Pharma—Market Access Networking Session![]() Kiersten Combs Moderator:![]() Joan McCormick |
8:45 |
Co-Chairs’ Opening Remarks |
9:00 |
KEYNOTEStatus Report from the Canadian Drug Agency Transition Office![]() Susan Fitzpatrick Stakeholders from across the pharmaceutical and healthcare sector have been eagerly awaiting details of the Government of Canada’s pharmacare strategy. The Canadian Drug Agency Transition Office was established in spring of 2021 to work with provinces, territories and key stakeholders on options for a Canadian Drug Agency (CDA.) A proposal for advancing with a CDA has been informed by analysis and over 275 meetings and roundtables with key stakeholders and partners. These meetings underscored the need for national leadership in addressing key system gaps and improving the Canadian pharmaceuticals landscape for the benefit of all Canadians.
A principled approach is envisioned that prioritizes respect for jurisdiction, builds on system strengths, and focuses on the continued involvement of patients and stakeholders. This session will put a spotlight on key initiatives being undertaken by the transition office including:
|
9:30 |
CADTH TOWNHALLFrom Strengthening International HTA Collaboration and Stakeholder Engagement to Post Market Evaluations: Key Developments for Manufacturers to Watch in the Year Ahead![]() Suzanne McGurn
|
10:15 |
Morning Coffee and Networking Break |
10:30 |
The Next Chapter of RWE in Canada: Empowering Access and Reimbursement Decisions through a National Data Strategy![]() Jaclyn Beca ![]() Dr. Nicole Mittmann ![]() Dr. Daria O’Reilly ![]() Mina Tadrous
|
11:30 |
Implementing Innovative Agreements in Canada with Lessons Learned Internationally![]() Karen Facey ![]() Amyn Sayani, Ph.D. ![]() Nicole Yada
|
12:15 |
Networking Lunch |
1:15 |
How to Build an Effective Rare Disease Drug Access Strategy in Canada: Examining What’s Working, What’s Not, and Alternative Pathways for Exploration![]() Durhane Wong-Rieger ![]() Fred Little Moderator:![]() Farah Jivraj
|
2:15 |
Networking Break |
2:45 |
Benchmarking with B.C.: Analyzing How the Biosimilars Switch Policy has Impacted Drug Spending and Health Outcomes![]() Mark Harrison It has been three years since B.C. embarked upon its non-medical biosimilar switch policy. Since that time, Ontario, Quebec, and other provinces across Canada have indicated that they will deploy similar strategies, but little has been revealed about the tack or timeline. With B.C.’s phased approach completed, and more provinces to follow, it is a critical time to examine whether the province’s objectives are being met. This session will provide key takeaways from financial and health data. Points of discussion include:
|
3:30 |
Case StudyExamining the Expansion of Private Payer Coverage for Obesity Management Drugs and the Implications for Other Therapeutic Areas![]() Priti Chawla ![]() Rosemarie Childerhose ![]() Dr. Sean Wharton ![]() Sandra Elia The private payer market is starting to shift, with expanded coverage for obesity management drugs, like smoking cessation drugs before it. What was once looked at as a lifestyle issue, has evolved to reflect a deeper understanding of obesity of chronic disease. This session will put a spotlight on how reimbursement is expanding, and what this could indicate about the market for medications in other therapeutic areas. |
4:30 |
Conference Adjourns |
Day 2 - Friday, January 20, 2023
8:45 |
Co-Chairs’ Opening Remarks |
9:00 |
Focus on Precision Medicine Part IAssessing the Canadian State of Readiness for Patient Access in the Age of Genomic Medicine![]() Don Husereau
|
9:30 |
PART IIPan-Canadian Panel: How to Optimize the Delivery of Genetic and Advanced Diagnostic Testing for Personalized Therapies![]() Harriet E Feilotter ![]() Craig Ivany ![]() Paul Kryzanowski Moderator:![]() Don Husereau This pan-Canadian panel discussion will explore next steps for adoption and implementation across Canada. Panelists will explore:
|
10:30 |
Morning Coffee Break |
11:00 |
The Evolution of Drug Pricing in Canada: How to Meet the PMPRB’s New Guidelines for the Final Regulations![]() Daphne Lainson Amendments to the Patented Medicines Price Review Board regulations came into force in July 2022, with a “status quo” interim approach to price assessments in the absence of new guidelines to assist manufacturers in the prepare for the changes. The most consequential change being the new basket of comparator countries for reference pricing. This session will provide practical guidance on the pricing mechanisms being used, and key considerations for manufacturers.
|
11:45 |
Negotiating with the pCPA in 2023: Practical Insights on Timelines, the TNP, and the Future of Value Based Agreements![]() Dominic Tan
|
12:30 |
Networking Lunch |
1:30 |
Hot Topics in Digital Health and InnovationINESSS: Quebec’s Strategy to Accelerate Access to Innovative Medicines and Health Technology![]() Sylvie Bouchard
|
2:15 |
Leveraging Digital Health Tools: Assessing the Impact of New Models of Care on the Market Access Landscape![]() Onil Bhattacharyya ![]() Louise Binder
|
3:00 |
Networking Break |
3:30 |
The Role of Pharmacists in Frontline Care: Exploring Opportunities to Expand the Scope of Practice for Timely Patient Access![]() Nina Lathia The role of retail pharmacies is evolving: an essential patient access point for pharmaceuticals, is now becoming more active in the delivery of front-line care. During the COVID-19 pandemic pharmacists helped alleviate pressure on the health system by administering tests and delivering vaccinations. Many provinces across Canada are now expanding pharmacists’ scope of practice to prescribe certain medications. This session will examine current and future opportunities for pharmacists to assess, prescribe and deliver care – and the implications for both patients and manufacturers.
|
4:15 |
Breaking Down the Latest Changes in US. Drug Pricing and the Potential Impact on the Canadian Market![]() Erin E. Atkins
|
5:00 |
Conference Concludes |